Association of linezolid interruption and rechallenge with clinical outcomes in patients with rifampicin-resistant tuberculosis in South Africa, 2018–22: an observational cohort study
Authors:
Open Access
- 17 March 2026
- journal article
- research article
- Published by Elsevier in The Lancet Global Health
- Vol. 14 (4) , e579-e588
Abstract
No abstract availableKeywords
Funding Information
- European and Developing Countries Clinical Trials Partnership
- South African Medical Research Council
This publication has 23 references indexed in Scilit:
- Multidrug-resistant tuberculosisNature Reviews Disease Primers, 2024
- Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerationsExpert Review of Clinical Pharmacology, 2023
- A 24-Week, All-Oral Regimen for Rifampin-Resistant TuberculosisNew England Journal of Medicine, 2022
- Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant TuberculosisNew England Journal of Medicine, 2022
- Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and InterpretationJACC: Heart Failure, 2020
- Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysisThe Lancet Respiratory Medicine, 2020
- Treatment of Highly Drug-Resistant Pulmonary TuberculosisNew England Journal of Medicine, 2020
- Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimenInternational Journal of Infectious Diseases, 2019
- Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysisThe Lancet, 2018
- A Triad of Linezolid Toxicity: Hypoglycemia, Lactic Acidosis, and Acute PancreatitisBaylor University Medical Center Proceedings, 2015